#USA #Class Action #New Orleans #Kahn Swick Foti #ADMA Biologics

Important Class Action Lawsuit Notice for ADMA Biologics Investors

On June 19, 2026, Kahn Swick & Foti, LLC (KSF), along with its partner and former Louisiana Attorney General Charles C. Foti, Jr., issued a significant notice to investors in ADMA Biologics, Inc. regarding an ongoing class-action securities lawsuit. This announcement serves as a reminder for those affected by the company’s actions, with an important deadline looming on August 10, 2026, for investors wishing to participate in the suit.

Overview of the Class Action Lawsuit

The class action is specifically aimed at investors who acquired securities from ADMA Biologics during the period spanning from August 9, 2024, to March 25, 2026. The lawsuit, registered in the United States District Court for the District of New Jersey, seeks to recover financial losses incurred during this timeframe as a result of alleged misinformation from the company.

Allegations Against ADMA Biologics

According to the complaint filed in this case (Mazzarino v. ADMA Biologics, Inc., et al, No. 26-cv-04793), crucial claims have been made against ADMA Biologics and certain executives, stating that they failed to disclose material information that could have influenced investor decisions. The accusations suggest the following violations of federal securities laws:

1. Undisclosed Related Party Transaction: The lawsuit indicates that ADMA Biologics may have engaged in undisclosed transactions with related parties, which could have significant implications for financial statements and investor trust.
2. Channel Stuffing: Allegations include that the company used practices such as channel stuffing to artificially inflate revenue figures, misleading investors regarding the true state of its business performance.
3. Lack of Internal Controls: The complaint asserts that the company lacked adequate internal controls, raising concerns about its governance and operational integrity.
4. False Statements: As a result of these issues, the lawsuit claims that the company’s disclosures regarding its business, operations, and future prospects were materially inaccurate and misleading.

Legal Rights of Investors

For investors who believe they were negatively affected by these actions, it is vital to act before the August 10, 2026 deadline if they wish to be considered for a lead plaintiff role in the case. However, it's important to note that participation as a lead plaintiff is not a prerequisite for recovering losses sustained during the class period. Investors can still share in any recovery provided a successful outcome is achieved in the lawsuit.

Contact Information for Investors

Those interested in more details or seeking partnership in the lawsuit are encouraged to reach out to KSF Managing Partner Lewis Kahn. He can be contacted toll-free at 1-877-515-1850 or via email at [email protected]. For further information about the class action and how to get involved, investors can also visit the official KSF website.

About Kahn Swick & Foti, LLC

Kahn Swick & Foti, LLC is recognized as one of the leading boutique securities litigation law firms in the United States. Under the leadership of Charles C. Foti, Jr., the firm has been instrumental in representing public and private institutional investors, as well as retail investors recovering losses from fraudulent activities of publicly traded companies. In the previous year, they were ranked among the top 10 firms nationally based on total settlement value, showcasing their credentials in the legal landscape.

In closing, ADMA Biologics investors should consider this critical information carefully as the deadline approaches. It is essential to stay well-informed and proactive in navigating the legal options available regarding this significant lawsuit.